ArticleArXiv2024
Quantum-Enhanced Detection of Viral cDNA via Luminescence Resonance Energy Transfer Using Upconversion and Gold Nanoparticles.
Article in ArXiv, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
13 authors.
Funding
Abstract
The COVID-19 pandemic has profoundly impacted global economies and healthcare systems, revealing critical vulnerabilities in both. In response, our study introduces a groundbreaking method for the detection of SARS-CoV-2 cDNA, leveraging Luminescence resonance energy transfer (LRET) between upconversion nanoparticles (UCNPs) and gold nanoparticles (AuNPs) to achieve an unprecedented detection limit of 242 femtomolar (fM). This innovative sensing platform utilizes UCNPs conjugated with one primer and AuNPs with another, targeting the 5' and 3' ends of the SARS-CoV-2 cDNA, respectively, enabling precise differentiation of mismatched DNA sequences and significantly enhancing detection specificity. Through rigorous experimental analysis, we established a quenching efficiency range from 10.4% to 73.6%, with an optimal midpoint of 42%, thereby demonstrating the superior sensitivity of our method. By comparing the quenching efficiency of mismatched DNAs to the target DNA, we identified an optimal DNA:UCNP:AuNP ratio that ensures accurate detection. Our comparative analysis with existing SARS-CoV-2 detection methods revealed that our approach not only provides a lower detection limit but also offers higher specificity and potential for rapid, on-site testing. This study demonstrates the superior sensitivity and specificity of using UCNPs and AuNPs for SARS-CoV-2 cDNA detection, offering a significant advancement in rapid, accessible diagnostic technologies. Our method, characterized by its low detection limit and high precision, represents a critical step forward in managing current and future viral outbreaks, contributing to the enhancement of global healthcare responsiveness and infectious disease control.
Indexed as
Identifiers
39483352PMC11527101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.